1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson

Plenary Session

Vinay Prasad, MD MPH

Policy, Oncology, Science & Medicine, Medicine, Health

4.8 • 798 Ratings

🗓️ 4 April 2019

⏱️ 60 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X Rivaroxaban: doi.org/10.1056/NEJMoa1814630 Apixaban: doi.org/10.1056/NEJMoa1814468 Back us on Patreon! www.patreon.com/plenarysession

Transcript

Click on a timestamp to play from that location

0:00.0	You're listening to Plenary Session.
0:09.3	On this week's episode of Plenary Session, we're going to get back to what we do best,
0:13.8	talking about hard-hitting research that appeared in recent high-profile journals,
0:18.2	including Lancet Oncology and two paired papers in the New England
0:20.9	Journal of Medicine. I'm going to talk about Bill Cap, a study with a P-value of 0.097, and that
0:27.5	P-value these days is considered close enough and good enough than practice changing by many, although
0:32.7	I have a few bones to pick with that argument. Next, I'll be talking to Sven Olson.
0:38.3	Yes, he's back by popular demand.
0:40.5	Sven Olson is a classical hematologist who's going to take you through recent studies
0:45.2	that test whether or not DOACs should be administered to patients with advanced or metastatic
0:50.2	malignancies and high corona scores as a prophylactic agent against VTE.
0:55.4	You won't want to miss our dissection of these clinical trials.
0:58.8	Stay tuned.
1:02.0	But first, a plug.
1:04.1	If you like this podcast, do us a favor and recommend it to a friend.
1:08.9	Plenary Session wants to grow its audience,
1:10.8	and the best way to do so is to get a personal recommendation from someone you know or trust. So recommend it to someone and have them check out an episode. Also, consider supporting us on Patreon.
1:22.7	Patreon.com allows you to support artists or podcasts that you appreciate, and if you like this podcast,
1:27.9	that's a great way to show your support.
1:29.7	Finally, if you haven't yet gone on to the iTunes store and written us a review, we
1:33.8	greatly appreciate it.
1:35.0	Tell us what you think about this podcast, and give us five stars if we've earned it.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.